Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma
Cells · 27.10.2023 · 12 (21) · 2534
DOI: 10.3390/cells12212534 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 27.10.2023. Verfasst von Giulia Vallini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Skin Neoplasms, Antineoplastic Agents, Basal Cell Carcinoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-melanoma skin cancers (NMSCs) are the most common human neoplasms world-wide. In detail, basal cell carcinoma (BCC) is the most frequent malignancy in the fair-skinned population. The incidence of BCC remains difficult to assess due to the poor registration practice; however, it has been increasing in the last few years. Approximately, 85% of sporadic BCCs carry mutations in Hedgehog pathway genes, especially in PTCH, SUFU and SMO genes, which lead to the aberrant activation of GLI transcriptional factors, typically silent in cells of adult individuals. The management of advanced BCC (aBCC), both metastatic (mBCC) and locally advanced BCC (laBCC), not candidates for surgical excision or radiotherapy, remains challenging. The discovery of mutations in the Hh signaling pathway has paved the way for the development of Hh pathway inhibiting agents, such as vismodegib and sonidegib, which have represented a breakthrough in the aBCC management. However, the use of these agents is limited by the frequent occurrence of adverse events or the development of drug resistance. In this review, we thoroughly describe the current knowledge regarding the available options for the pharmacological management of aBCCs and provide a forward-looking update on novel therapeutic strategies that could enrich the therapeutic armamentarium of BCC in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
- Department of Medical, Surgical and Neurological Sciences, Division of Dermatology, University of Siena, 53100 Siena, Italy.
- Institute of Dermatology, Catholic University of the Sacred Heart, 00168 Rome, Italy.
- Department of Haematology, Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, 00165 Rome, Italy.
- Department of Medical, Surgical and Neurological Sciences, Division of Rheumatology, University of Siena, 53100 Siena, Italy.
ORCID-Profile: Giulia Vallini, Laura Calabrese, Linda Tognetti
Zitieren
APA
Vallini, G., Calabrese, L., Canino, C., Trovato, E., Gentileschi, S., Rubegni, P., & Tognetti, L. (2023). Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma. Cells, 12(21), 2534. https://doi.org/10.3390/cells12212534
Vancouver
Vallini G, Calabrese L, Canino C, Trovato E, Gentileschi S, Rubegni P, et al. Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma. Cells. 2023;12(21):2534. doi:10.3390/cells12212534
BibTeX
@article{Vallini2023,
author = {Vallini, Giulia and Calabrese, Laura and Canino, Costanza and Trovato, Emanuele and Gentileschi, Stefano and Rubegni, Pietro and Tognetti, Linda},
title = {Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma},
journal = {Cells},
year = {2023},
volume = {12},
number = {21},
pages = {2534},
doi = {10.3390/cells12212534}
}
EUVIMED